Tumor eradication by immunotherapy with biodegradable PLGA microspheres : an alternative to incomplete Freund's adjuvant

Müller, Marc; Schlosser, Eva; Gander, Bruno; Gröttrup, Marcus

Tumor eradication by immunotherapy with biodegradable PLGA microspheres : an alternative to incomplete Freund's adjuvant

Dateien

Mueller_tumor.pdfGröße: 5.46 MBDownloads: 870

Datum

2011

Autor:innen

Müller, Marc

Schlosser, Eva

Gander, Bruno

Gröttrup, Marcus

Open Access-Veröffentlichung

Open Access Green

Sammlungen

Biologie

Publikationstyp

Zeitschriftenartikel

Publikationsstatus

Published

Erschienen in

International Journal of Cancer. 2011, 129(2), pp. 407-416. ISSN 0020-7136. eISSN 1097-0215. Available under: doi: 10.1002/ijc.25914

Zusammenfassung

In experimental tumor immunotherapy, incomplete Freund's adjuvant (IFA) has been considered as the “gold standard” for T-cell vaccination in mice and humans in spite of its considerable adverse effects. Recently, we succeeded in eliciting strong CTL responses in mice after vaccination with biodegradable poly(D,L-lactide-co-glycolide) (PLGA) microspheres (MS). In our study, we compared the immune response to IFA and PLGA-MS containing ovalbumin (OVA) and CpG-oligodeoxynucleotide (MS-OVA/CpG) or we used a mixture of MS-OVA/CpG and MS-polyI:C. A single vaccination with MS-OVA/CpG elicited long-lasting titers of IgG1 and IgG2a, but only low IgE titers, and also the T-cell response was biased toward Th1 differentiation. Antigen presentation to CD4+ and CD8+ cells and activation of a cytotoxic T-cell response in mice vaccinated with PLGA-MS and IFA lasted for over 3 weeks. Preconditioning of the injection site with TNF-α and heterologous prime-boost regimen further enhanced the cytotoxic response. PLGA-MS were as efficient or superior to IFA in eradication of preexisting tumors and suppression of lung metastases. Taken together, PLGA-MS are well-defined, biodegradable and clinically compatible antigen carrier systems that compare favorably with IFA in their efficacy of tumor immunotherapy in mouse models and hence deserve to be tested for their effectiveness against human malignant diseases.

Fachgebiet (DDC)

570 Biowissenschaften, Biologie

Schlagwörter

Microspheres, incomplete Freund's adjuvant, stimulation of T-cell proliferation, in vivo cytotoxicity, cancer

Zitieren

ISO 690

MÜLLER, Marc, Eva SCHLOSSER, Bruno GANDER, Marcus GRÖTTRUP, 2011. Tumor eradication by immunotherapy with biodegradable PLGA microspheres : an alternative to incomplete Freund's adjuvant. In: International Journal of Cancer. 2011, 129(2), pp. 407-416. ISSN 0020-7136. eISSN 1097-0215. Available under: doi: 10.1002/ijc.25914

BibTex

@article{Muller2011-07-15Tumor-16315,
  year={2011},
  doi={10.1002/ijc.25914},
  title={Tumor eradication by immunotherapy with biodegradable PLGA microspheres : an alternative to incomplete Freund's adjuvant},
  number={2},
  volume={129},
  issn={0020-7136},
  journal={International Journal of Cancer},
  pages={407--416},
  author={Müller, Marc and Schlosser, Eva and Gander, Bruno and Gröttrup, Marcus}
}

RDF

<rdf:RDF
    xmlns:dcterms="http://purl.org/dc/terms/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:bibo="http://purl.org/ontology/bibo/"
    xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#"
    xmlns:foaf="http://xmlns.com/foaf/0.1/"
    xmlns:void="http://rdfs.org/ns/void#"
    xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > 
  <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/16315">
    <dc:contributor>Gröttrup, Marcus</dc:contributor>
    <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dc:contributor>Gander, Bruno</dc:contributor>
    <dcterms:rights rdf:resource="https://rightsstatements.org/page/InC/1.0/"/>
    <dc:creator>Müller, Marc</dc:creator>
    <dc:contributor>Müller, Marc</dc:contributor>
    <dspace:hasBitstream rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/16315/2/Mueller_tumor.pdf"/>
    <foaf:homepage rdf:resource="http://localhost:8080/"/>
    <dcterms:title>Tumor eradication by immunotherapy with biodegradable PLGA microspheres : an alternative to incomplete Freund's adjuvant</dcterms:title>
    <dcterms:hasPart rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/16315/2/Mueller_tumor.pdf"/>
    <dc:creator>Schlosser, Eva</dc:creator>
    <dc:creator>Gander, Bruno</dc:creator>
    <dcterms:abstract xml:lang="eng">In experimental tumor immunotherapy, incomplete Freund's adjuvant (IFA) has been considered as the “gold standard” for T-cell vaccination in mice and humans in spite of its considerable adverse effects. Recently, we succeeded in eliciting strong CTL responses in mice after vaccination with biodegradable poly(D,L-lactide-co-glycolide) (PLGA) microspheres (MS). In our study, we compared the immune response to IFA and PLGA-MS containing ovalbumin (OVA) and CpG-oligodeoxynucleotide (MS-OVA/CpG) or we used a mixture of MS-OVA/CpG and MS-polyI:C. A single vaccination with MS-OVA/CpG elicited long-lasting titers of IgG1 and IgG2a, but only low IgE titers, and also the T-cell response was biased toward Th1 differentiation. Antigen presentation to CD4+ and CD8+ cells and activation of a cytotoxic T-cell response in mice vaccinated with PLGA-MS and IFA lasted for over 3 weeks. Preconditioning of the injection site with TNF-α and heterologous prime-boost regimen further enhanced the cytotoxic response. PLGA-MS were as efficient or superior to IFA in eradication of preexisting tumors and suppression of lung metastases. Taken together, PLGA-MS are well-defined, biodegradable and clinically compatible antigen carrier systems that compare favorably with IFA in their efficacy of tumor immunotherapy in mouse models and hence deserve to be tested for their effectiveness against human malignant diseases.</dcterms:abstract>
    <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2012-01-04T10:54:09Z</dc:date>
    <dc:language>eng</dc:language>
    <dc:rights>terms-of-use</dc:rights>
    <dcterms:issued>2011-07-15</dcterms:issued>
    <bibo:uri rdf:resource="http://kops.uni-konstanz.de/handle/123456789/16315"/>
    <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2013-03-31T22:25:04Z</dcterms:available>
    <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dc:creator>Gröttrup, Marcus</dc:creator>
    <dc:contributor>Schlosser, Eva</dc:contributor>
    <dcterms:bibliographicCitation>First publ. in: International Journal of Cancer ; 129 (2011), 2. - pp. 407-416</dcterms:bibliographicCitation>
  </rdf:Description>
</rdf:RDF>

Universitätsbibliographie

Ja